Damage of the endothelial GCX at the BBB caused by neuroinflammation was observed in patients with early-stage MS as indicated by the increased presence of GCX degradation markers heparin sulfate, hyaluronan, and syndecan-1 [68,73]. This evidence concerns the gene SDC1 and myeloid sarcoma.